Document 2834
 DOCN  M94A2834
 TI    Effect of fluconazole (FLU) on the clinical pharmacokinetics of
       delavirdine (DLV).
 DT    9412
 AU    Cox S; Anderson RD; Driver M; Carel B; Upjohn Company, Kalamazoo, MI.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):214 (abstract no. PB0284). Unique
       Identifier : AIDSLINE ICA10/94369741
 AB    OBJECTIVE: DLV is a non-nucleoside RT inhibitor with clearance mediated
       by Cytochrome P4503A. The purpose of this study was to evaluate the
       effects of multiple doses of FLU, a P4503A inhibitor, on the
       steady-state pharmacokinetics (PK) of DLV in HIV+patients. METHODS:
       Thirteen HIV-1 patients (12 males, 1 female; CD4 = 160-480/mm3) received
       DLV 300 mg TID for 30 days. A control group (CON, n = 5) received only
       DLV and a FLU group (n = 8) received FLU 400 mg QD on Days 16-30.
       RESULTS: DLV PK parameter values did not differ significantly between
       the two groups on Day 15 and between Days 15 and 30 for the CON group.
       Mean (SD) DLV parameter values from the FLU group are listed below:
       TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSION: FLU has no clinically
       significant effect on the steady-state PK of DLV.
 DE    Antiviral Agents/*PHARMACOKINETICS/THERAPEUTIC USE  Comparative Study
       Cytochrome P-450/METABOLISM  Drug Interactions  Female
       Fluconazole/*PHARMACOKINETICS/THERAPEUTIC USE  Half-Life  Human  HIV
       Infections/DRUG THERAPY  Indoles/*PHARMACOKINETICS/THERAPEUTIC USE  Male
       Metabolic Clearance Rate  Piperazines/*PHARMACOKINETICS/THERAPEUTIC USE
       Reverse Transcriptase/ANTAGONISTS & INHIB  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).